A study recently published by the International Journal of Chronic Obstructive Pulmonary Disease (COPD), analyzes current recommendations for palliative care (PC) for chronic obstructive pulmonary disease (COPD) patients to determine their level of reliability during an expected 1-year mortality.
PC is typically used for patients with neoplastic diseases and may be used with other therapies to improve symptoms and the overall quality of life. PC has proven to be effective in COPD, but it is more complicated in utilization.
"One of the main barriers for initiating PC in COPD is the unpredictability of vital prognosis in an individual patient," the authors wrote. "Many COPD patients present a gradual deterioration, others stability for years, while a subgroup suffers acute COPD exacerbations."
The study involved 3 main phases to determine the reliability of PC for COPD patients:
Of the 697 patients hospitalized for COPD exacerbation included in the study, 93% were males and had a 1-mortality rate of 17.5%. However, of those whom met the criteria for PC, there was not a statistical significance in mortality differences.
“The main conclusion of our study is that none of the suggested criteria for initiating PC based on an expected poor vital prognosis in COPD patients in the short or medium term offers sufficient reliability, and perhaps, they should be avoided as exclusive criteria for considering PC or at least critically evaluated,” the authors concluded.
Despite the lack of statistical differences, the researchers suggested that the decision to begin PC should be paired with restorative care. Furthermore, PC is often associated with only being necessary for terminal care, but the study recommended considering its applicability when used with other therapies.
Racial Differences in CA-125 Levels Tied to Ovarian Cancer Treatment Delays
April 17th 2025Black and American Indian women with ovarian cancer were less likely to have elevated cancer antigen 125 (CA-125) levels at diagnosis, resulting in delayed chemotherapy initiation and highlighting the need for more inclusive guidelines.
Read More
SGLT2 Inhibitors Show Renal Benefits in HF and CKD as Prescribers Target Uptake Gaps
April 15th 2025Abstracts featured at the National Kidney Foundation Spring Clinical Meeting highlighted the renoprotective benefits of SGLT2 inhibitors in heart failure and diabetic kidney disease while emphasizing the need for strategies to increase their uptake in primary care.
Read More